• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Earlier need of infliximab intensification in ulcerative colitis than in Crohn's disease.

作者信息

Magro Fernando, Rodrigues-Pinto Eduardo, Lopes Susana, Macedo Guilherme

机构信息

Gastroenterology Department, Centro Hospitalar São João, Porto, Portugal; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Portugal; MedInUP - Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal.

Gastroenterology Department, Centro Hospitalar São João, Porto, Portugal.

出版信息

J Crohns Colitis. 2014 Oct;8(10):1331-2. doi: 10.1016/j.crohns.2014.03.007. Epub 2014 Mar 29.

DOI:10.1016/j.crohns.2014.03.007
PMID:24690137
Abstract
摘要

相似文献

1
Earlier need of infliximab intensification in ulcerative colitis than in Crohn's disease.溃疡性结肠炎比克罗恩病更早需要强化英夫利昔单抗治疗。
J Crohns Colitis. 2014 Oct;8(10):1331-2. doi: 10.1016/j.crohns.2014.03.007. Epub 2014 Mar 29.
2
Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.克罗恩病和溃疡性结肠炎中强化英夫利昔单抗剂量的必要性。
World J Gastroenterol. 2014 Jul 21;20(27):9170-7. doi: 10.3748/wjg.v20.i27.9170.
3
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.与英夫利昔单抗相比，接受阿达木单抗治疗的克罗恩病门诊患者出现继发性反应丧失和需要增加剂量的时间更早：一项真实队列研究。
J Crohns Colitis. 2014 Nov;8(11):1454-63. doi: 10.1016/j.crohns.2014.05.007. Epub 2014 Jun 16.
4
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.英夫利昔单抗治疗炎症性肠病患者的抗药物抗体的时间演变。
Gut. 2014 Aug;63(8):1258-64. doi: 10.1136/gutjnl-2013-305259. Epub 2013 Sep 16.
5
Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.炎症性肠病患者输注 1 小时 10mg/kg 英夫利昔单抗的耐受性。
J Crohns Colitis. 2013 Mar;7(2):129-33. doi: 10.1016/j.crohns.2012.03.007. Epub 2012 Apr 1.
6
Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.炎症性肠病患者输注 1 小时 10mg/kg 英夫利昔单抗的耐受性：一项前瞻性多中心队列研究。
J Crohns Colitis. 2014 Feb;8(2):161-5. doi: 10.1016/j.crohns.2013.08.004. Epub 2013 Aug 30.
7
Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.溃疡性结肠炎和克罗恩病女性的分娩结局以及抗炎药物治疗的药物流行病学方面
Dan Med Bull. 2011 Dec;58(12):B4360.
8
Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.在79例接受英夫利昔单抗维持治疗的炎症性肠病（IBD）患者队列中检测英夫利昔单抗谷浓度及抗英夫利昔单抗抗体。
J Crohns Colitis. 2014 Aug;8(8):881-9. doi: 10.1016/j.crohns.2014.01.009. Epub 2014 Jan 31.
9
Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.体重指数增加与炎症性肠病患者对英夫利昔单抗的反应丧失时间提前有关。
Inflamm Bowel Dis. 2013 Sep;19(10):2118-24. doi: 10.1097/MIB.0b013e31829cf401.
10
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.与英夫利昔单抗治疗失败的克罗恩病患者强化剂量治疗相比，个体化治疗是一种长期具有成本效益的方法。
Dig Dis Sci. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015 Feb 12.

引用本文的文献

1
Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis.炎症性肠病中经验性抗TNF剂量强化的频率和有效性：系统评价与荟萃分析
J Clin Med. 2021 May 14;10(10):2132. doi: 10.3390/jcm10102132.
2
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.英夫利昔单抗剂量递增作为治疗溃疡性结肠炎继发反应丧失的有效策略。
Dig Dis Sci. 2015 Oct;60(10):3075-84. doi: 10.1007/s10620-015-3735-4. Epub 2015 Jun 5.